On Monday, Shares of Macy’s Inc (NYSE:M), subtract -1.31% and closed at $34.57 in the last trading session. The last trading range of the stock ranges between $37.44 and $37.48. The company’s Market capitalization is $11.69 Billion with the total Outstanding Shares of 308.47million. For the past decade, Redwood City-based Balsam Hill has been spreading Christmas cheer to families around the world with its highly-realistic artificial Christmas trees and holiday décor. To celebrate its 10th anniversary, Balsam Hill is partnering with Macy’s (NYSE:M) to debut “Deck The Halls,” a wondrous float bringing the magic of Christmas to life in the 90th Anniversary Macy’s Thanksgiving Day Parade®. For more than 3.5 million spectators and more than 50 million viewers nationwide, the Macy’s Parade signifies the starting of the holiday season and Balsam Hill is happy to be part of such a long-standing tradition. As part of the 10-year celebration, Balsam Hill is giving away a trip for four to New York City to attend the Parade and witness the float make its debut.
Standing more than 30 feet tall, Balsam Hill’s “Deck The Halls” will embody all that is Christmas – from toys and decorated trees to entertainment and joy. Modeled after the traditional wooden pyramid, each of the three levels are hand-carved and hand-painted by the Macy’s Parade Studio to encapsulate different aspects of the holiday season enjoyed around the world. “Knowing who Balsam Hill was, for us, we right away zeroed in on authenticity. We wanted things to have that kind of detail and overall beauty,” said John Piper, vice president of Macy’s Parade Studio. He added, “This one was just a real work of joy and love for us.”
Myriad Genetics, Inc. (NASDAQ:MYGN), dropped -11.60% and closed at $18.87 in the last trading session. The last trading range of the stock ranges between $18.58 and $21.01. The company’s Market capitalization is $1.31 Billion with the total Outstanding Shares of 69.13 million. During the 52-week trading session the minimum price at which share price traded, registered at $18.58 and reached to max level of $46.24. Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, recently declared that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone. The myChoice HRD test was evaluated in the NOVA study (NCT01847274) of nirarapib, an investigational oral PARP inhibitor being developed by TESARO (TSRO).
Recently`s declarement follows publication of the NOVA study in the New England Journal of Medicine. NOVA is a well-controlled Phase 3 trial of niraparib that enrolled 553 patients with recurrent ovarian cancer who responded to their most recent platinum-based chemotherapy. This trial was designed to assess progression free survival (PFS) in a broad population of patients who were assigned to one of two cohorts based upon germline BRCA mutation status.
“Patients with ovarian cancer who tested positive with myChoice HRD practiced a clinically meaningful improvement in PFS,” said Johnathan Lancaster, M.D., Ph.D., gynecologic oncologist and chief medical officer of Myriad Genetic Laboratories. “We estimate that myChoice HRD identifies more than double the number of patients who may benefit contrast to germline BRCA testing alone.”
On the otherhand Rowan Companies PLC (NYSE: RDC), jumped 2.27% and closed at $15.33 in the last trading session. The last trading range of the stock ranges between $15.20 and $15.59. The company’s Market capitalization is $1.91 Billion with the total Outstanding Shares of 125.42 million. During the 52-week trading session the minimum price at which share price traded, registered at $10.67 and reached to max level of $21.83. Rowan Companies plc (“Rowan” or the “Company”) (RDC) plans to report earnings for the three months ended September 30, 2016 on Tuesday, November 1, 2016, before the open of the financial markets in the United States. Following the earnings report, the Company will conduct a conference call at 10:00 a.m. Central Time to discuss its operating results. Interested parties can listen to the conference call by telephone or over the internet.
Individuals who wish to take part on the conference call by telephone should dial-in about five to 10 minutes before the planned start time, using one of the numbers offered below.
877-201-0168 (U.S. and Canada)
68158114 Conference ID
In addition, the conference call will be simulcast through a listen-only broadcast over the internet and can be accessed by logging on at the Company’s website.